Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Abivax S.A. (Euronext Paris: ABVX)

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral drugs and human therapies to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months. ABX464 has been developed using ABIVAX’ anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients’ clear important pathogenic viruses. Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy. ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). *


Period Start 2013-12-27 restructured
  Group Abivax (Group)
Products Industry therapeutic vaccine
  Industry 2 virostatic agent
Persons Person Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD)
  Person 2 Kenny, Daniel (Abivax 201410– COO + VP Business Development before Baxter Vaccines + Baxter BioScience)
Region Region Paris
  Country France
  Street 5 rue de la Baume
  City 75008 Paris
  Tel +33-1-5383-0841
    Address record changed: 2024-01-05
Basic data Employees B: 11 to 50 (2023-06-30)
  Currency EUR
  Annual sales 4,583,000 (income, operating, total (2022) 2022-12-31)
  Profit -60,740,000 (2022-12-31)
  Cash 26,950,000 (2022-12-31)
    * Document for »About Section«: 
Record changed: 2024-04-03


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Abivax (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top